Compare Jones Lang LaSalle Inc (JLL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Mesoblast Limited — how do they compare? Jones Lang LaSalle Inc trades at $303.6 (market cap $13.95B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Jones Lang LaSalle Inc is far larger — about 8× Mesoblast Limited's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Mesoblast Limited for 14 Days on average.
| JLL | MESO | |
|---|---|---|
Market Cap | $13.95B | $1.75B |
Volume | 457,462 | 239,027 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $20.96 |
52-Week Low | $280.16 | $13.19 |
Typical Hold Time | 71 Days | 14 Days |
Enterprise Value | $16.71B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $296.66, down 2.29% over 24 hours, with a bearish technical signal from moving averages and oscillators. The stock shows strong fundamentals with a P/E of 14.54, P/S of 0.53, and net income margin of 3.64%. Recent earnings have consistently beaten expectations, and cash flow from operations reached $1.19 billion in 2025. Analyst consensus is bullish with a $450.50 price target, supported by positive news on acquisitions and growth prospects.
The outlook for JLL is positive due to robust earnings growth, improving profit margins, and strategic acquisitions. Risks include market volatility, competitive pressures in real estate services, and economic sensitivity. Institutional sentiment remains strong, with a majority of analysts recommending buy. The stock presents a value opportunity if it can sustain its operational momentum amid broader market headwinds.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
